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OBJECTIVE—Morbid obesity may be accompanied by diabetes
and painful diabetic neuropathy, a poorly understood condition
that is manifested by mechanical or thermal allodynia and
hyperalgesia. Recent studies have highlighted the importance of
T-type calcium channels (T-channels) in peripheral nociception;
therefore, our goal was to examine the function of these channels
in the pathophysiology and development of painful diabetic
neuropathy.
RESEARCH DESIGN AND METHODS—In vivo testing of
mechanical and thermal sensation, morphometric peripheral
nerve studies, and electrophysiological and biochemical mea-
surements were used to characterize the role of T-channels and
the development of painful diabetic neuropathy in leptin-deﬁ-
cient (ob/ob) mice.
RESULTS—We found that ob/ob mice developed signiﬁcant
mechanical and thermal hypersensitivity early in life that coin-
cided with hyperglycemia and was readily reversed with insulin
therapy. These disturbances were accompanied by signiﬁcant
biophysical and biochemical modulation of T-channels in dorsal
root ganglion neurons as measured by a large increase in the
amplitude of T-currents and the expression of mRNA. The most
prevalent subtype, 1H (Cav3.2), was most strongly affected.
Moreover, (3,5,17)-17-hydroxyestrane-3-carbonitrile (ECN),
a novel neuroactive steroid and selective T-channel antagonist,
provided dose-dependent alleviation of neuropathic thermal and
mechanical hypersensitivity in diabetic ob/ob mice.
CONCLUSIONS—Our results indicate that pharmacological
antagonism of T-channels is potentially an important novel
therapeutic approach for the management of painful diabetic
neuropathy. Diabetes 58:2656–2665, 2009
I
t is predicted that more than 200 million people
worldwide will have type 2 diabetes by 2025 (1). A
common complication of diabetes is peripheral dia-
betic neuropathy (PDN), which is often marked by
mechanical and thermal allodynia and hyperalgesia and
cannot yet be treated effectively because of the lack of
knowledge of its pathophysiology (2,3).
Recent studies with leptin-deﬁcient (ob/ob) mice, an
animal model of morbid obesity and type 2 diabetes (4),
have suggested that PDN is commonly manifested as
mechanical allodynia (5), nerve conduction deﬁcits, mor-
phological and metabolic abnormalities of peripheral
nerves (both large motor and sensory ﬁbers and small
sensory ﬁbers), the spinal cord, and dorsal root ganglia
(DRG), indicating that ob/ob mice could be a useful model
for studying PDN and chronic pain states associated with
morbid obesity similar to those states that occur in
humans.
Although the effective treatment of chronic pain re-
mains elusive, recent ﬁndings suggest the importance of
T-channels in peripheral nociception, raising the possi-
bility that modulation of those channels might be ther-
apeutic in the treatment of acute (6,7) and chronic (8)
pain. For example, it has been shown that pharmacological
blockade of T-channels with mibefradil and ethosuximide
(9), and with (3,5,17)-17-hydroxyestrane-3-carbonitrile
(ECN) (10), alleviates mechanical hypersensitivity induced
by peripheral nerve injury in rats. Additional evidence regard-
ing the importance of peripheral T-channels in nociception
has been provided by the antisense study of Bourinet et al.
(11) involving isoform-speciﬁc oligonucleotides that down-
regulate each of the three isoforms of pore-forming subunits
of T-channel, Cav3.1 (1G), Cav3.2 (1H), and Cav3.3 (1I), in
DRG cells. In this study, only the oligonucleotides downregu-
lating the mRNA of Cav3.2 were effective in alleviating
thermal and mechanical hypersensitivity in the rat model of
mononeuropathy. Moreover, Cav3.2 knockout mice were
shown to have decreased responses to acute noxious stimuli
(12), further suggesting that T-channels are crucial in
nociception.
Furthermore, rats with streptozotocin (STZ)-induced
type 1 PDN have signiﬁcant enhancement of T-current–
dependent cellular excitability in acutely dissociated DRG
neurons (13). However, behavioral data that would pro-
vide a possible mechanistic link between the upregulation
of T-currents and symptoms of hyperalgesia in PDN are
lacking. Thus, we examined whether these channels are
important in the pathophysiology and development of
painful PDN in an animal model of type 2 diabetes.
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Ethics approval was obtained for all experimental protocols from the University
of Virginia Animal Care and Use Committee, Charlottesville, VA. All experiments
were conducted in accordance with the Guide for the Care and Use of Laboratory
Animals adopted by the U.S. National Institute of Health. Every effort was made
to minimize animal suffering and the number of animals used.
Morbidly obese (ob/ob) female mice and their age-matched wild-type
counterparts (C57BL/65J), as well as 1H knockout female mice (1H/)
and their age-matched littermates (1H/), were studied between the ages
of 4 weeks and 30 weeks. It is important to discuss our choice of female mice
for this study. Despite the fact that females are more sensitive than males to
many pain conditions and that the majority of pain sufferers are women
(14–16), less than 8% of currently available animal pain studies include female
animals (16). This is in part because studying pain in females is complicated
by estrous cycle–dependent variability in nociceptive thresholds. Our behav-
ioral sensory testing of ob/ob mice was facilitated by the fact that these mice
remain indeﬁnitely prepubertal and without an estrous cycle (17) and was
motivated by the fact that there is a signiﬁcantly higher prevalence of obesity
among women than men (18). Furthermore, female mice are easier to handle
during behavioral testing. The mice body weights and blood glucose levels
were monitored weekly by analyzing tail blood samples using an Accu-Check
glucometer (Roche Diagnostics, Indianapolis, IN).
Chemicals. ECN was freshly dissolved in a vehicle containing 15% cyclodex-
trin solution ([2-hydroxypropyl]--cyclodextrin solution; Sigma, St. Louis,
MO) and was balanced at pH 7.4 just before injection.
Behavioral testing
Assessment of thermal sensitivity. The paw withdrawal latency (PWL) to
thermal stimulation was measured as described previously (19–21) (also see
supplemental material, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-1763/DC1).
Assessment of mechanical sensitivity. The paw withdrawal response
(PWR) to mechanical stimulation was measured by our standard method
using von Frey ﬁlaments (6–8,10,13,22) (supplemental Material). This method
was modiﬁed from Chaplan et al. (23) to allow time for effective daily
assessment of mechanical sensitivity while minimizing residual behavioral
responses from repetitious testing (e.g., learning, habituation).
Assessment of sensorimotor abilities. The sensorimotor battery consisted
of three tests, the ledge, platform, and inclined screen, as described by Creeley
et al. (24) (supplemental material).
Statistical analysis. PWLs and PWRs were subjected to ANOVA containing
two within-subject variables: paw (right vs. left) and test session (before the
administration of vehicle or test compound vs. each posttreatment time point).
Two between-subject variables were the type of mouse (ob/ob vs. wild type or
1H/ vs. 1H/) and the age of the mouse. Relevant pairwise comparisons
were also done (Holm-Sidak method). -Levels were adjusted using the Bonfer-
roni procedure when appropriate. All data are expressed as means  SE. If data
did not show normal distribution, we used the Mann-Whitney rank sum test.
The thermal and mechanical hypersensitivity phenotype of ob/ob mice in
our study was conﬁrmed by three independent examiners. However, because
of differences in the size of wild-type and ob/ob mice, true blinding was not
possible. All drug injections were performed in a blinded manner.
Insulin administration. A group of ﬁve ob/ob mice received NPH insulin (Eli
Lilly and Company, Indianapolis, IN) in two daily intraperitoneal injections
from 8 to 12 weeks of age. The total daily dosage ranged from 10 to 40 units
and was based on morning glucose values. Control ob/ob and wild-type mice
received 0.2 ml saline i.p. twice daily.
Morphometry. Distal segments of the sural nerve were dissected, ﬁxed
overnight, sectioned, and analyzed as described in supplemental material.
Induction of diabetes. 1H/ and 1H/ animals received a single
intraperitoneal injection of 200 mg/kg STZ (Sigma) that had been freshly
prepared in saline (13). Mice that did not develop hyperglycemia within 3 days
post-STZ were excluded from the study.
Quantitative real-time PCR. Lumbar DRGs or the lumbar spinal cord were
dissected and prepared as we described previously (13) (see supplemental
material).
Electrophysiological studies. We analyzed data as reported elsewhere (25).
For one experiment, we dissected 6–8 lumbar DRGs as previously described
(13,26). We focused only on smaller cells having an average soma diameter of
20–30 m because previous studies have conﬁrmed that most of them are
likely to belong to unmyelinated and thinly myelinated polymodal nociceptors
in vivo (27,28).
RESULTS
Recent data indicate that ob/ob mice develop signs of PDN
(4,5) in the setting of transient and mild hyperglycemia
along with impaired glucose tolerance, hyperlipidemia,
and insulin resistance. Thus, we followed ob/ob mice and
their wild-type counterparts from 4 to 30 weeks of age
(Fig. 1). The body weight of ob/ob mice doubled by 10
weeks of age and tripled by 20 weeks as compared with
their weight at 4 weeks, although the weight gain in
wild-type mice was less than 55% (Fig. 1A).
Furthermore, ob/ob mice started to develop signiﬁcant
hyperglycemia with blood glucose levels 250 mg/dl (Fig.
1B, dashed line) at 7 weeks of age. The most severe
hyperglycemia occurred between the ages of 8 and 18
weeks. Although ob/ob mice remained morbidly obese, at
the age of about 20 weeks they had a spontaneous
decrease in blood glucose levels. Based on this observa-
tion, for the purpose of all our studies of PDN, we divided
ob/ob mice into three groups: obese but normoglycemic (4
to 7 weeks old); morbidly obese and hyperglycemic (8 to
20 weeks old, within the rectangle, Fig. 1A and B); and
morbidly obese but with reduced hyperglycemia (20
weeks old).
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FIG. 1. Age-dependent weight gain (A) and blood glucose levels (B)i n
ob/ob and wild-type mice. A: Ob/ob mice (F) rapidly gain weight from
the age of 4 weeks and are signiﬁcantly heavier than age-matched
wild-type mice () from 4 weeks of age (*P < 0.001). Compared with
4-week-olds, the body weight of ob/ob mice doubles around 10 weeks of
age and triples around 20 weeks of age, at which point it reaches a
plateau. Wild-type mice maintain steady body weight throughout the
entire age span (4 to 30 weeks of age) (n  12–24 ob/ob mice; n  12–24
wild-type mice). B: Ob/ob mice develop signiﬁcant hyperglycemia
(blood glucose levels >250 mg/dl) from 7 weeks of age and remain
hyperglycemic until 23 weeks of age (F). Spontaneous decrease in
blood glucose was recorded after the age of 23 weeks. Blood glucose
levels in wild-type matched controls () remains steady and within
normal limits throughout the entire age span (*P < 0.05 ob/ob vs.
wild-type mice). The area within the rectangle indicates ages (8 to 20
weeks old) when ob/ob mice are morbidly obese and signiﬁcantly
hyperglycemic (n  12–24 ob/ob mice; n  12–24 wild-type mice). WT,
wild type.
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tion, we studied mechanical (Fig. 2A) and thermal (heat)
sensitivity (Fig. 2B)i nob/ob mice at 4 to 27 weeks of age
and compared the ﬁndings to those from age-matched
wild-type mice. In Fig. 2, the area within the rectangle
highlights the group from 8 to 20 weeks of age, when
morbid obesity was accompanied by signiﬁcant hypergly-
cemia (as indicated in Fig. 1). Unlike wild-type mice,
which had fairly small weekly ﬂuctuations in mechanical
sensitivity, ob/ob mice started to develop mechanical hy-
persensitivity at 6 weeks; this sensitivity remained signif-
icant until 20 weeks of age (except for 18- and 19-week-old
mice) (Fig. 2A) at which point it subsided.
Beginning at 6 weeks of age, ob/ob mice were also
hypersensitive to noxious heat (Fig. 2B). Severe thermal
hypersensitivity was detected in ob/ob mice from 8 until 16
weeks of age, thus coinciding with hyperglycemia.
We considered the possibility that apparent resolution
of thermal and mechanical hypersensitivity in older ob/ob
mice can be a consequence of progressive damage to the
peripheral sensory nerves previously exposed to signiﬁ-
cant hyperglycemia. Thus, we performed a morphometric
study of sural nerves in mice 10–12 and 21–22 weeks old
using light microscopy. Of the measured parameters, there
were no signiﬁcant differences between age-matched ob/ob
and wild-type mice in total ﬁber number, ﬁber density,
ﬁber area and diameter, and axon area and diameter (n 
4 per group, P  0.05, data not shown). Between 10 and 12
weeks of age when ob/ob mice are at the peak of hyper-
glycemia, they exhibit evidence of peripheral neuropathy
manifested as a 19% decrease in myelin thickness and a
34% increase in axon-to-myelin area ratios compared with
age-matched wild-type mice (n  4 per group, P 	 0.05,
data not shown). When myelin thickness and axon-to-
myelin area ratios in mice 10–12 weeks old were com-
pared with those in mice 21–22 weeks old, we found no
difference between the two age-groups in either parame-
ter. This would suggest that improvement of sensory
symptoms in older ob/ob mice is less likely to be caused by
progressive deterioration of peripheral sensory ﬁbers.
To begin to understand the cellular and molecular
mechanisms of hyperalgesia associated with PDN in ob/ob
mice, we examined the electrophysiological properties of
T-currents and analyzed the expression of mRNA for the
three isoforms of T-channels in lumbar DRG neurons
obtained from ob/ob and wild-type mice (Fig. 3). First, we
used qRT-PCR to determine the expression of mRNA for
three isoforms of T-channels in lumbar DRGs from ob/ob
mice at 10–12 weeks of age and wild-type controls. We
found that the 1H isoform, as compared with 1G and I,
was the most prevalent in both wild-type (n  4) and ob/ob
mice (n  3). Importantly, we found that the levels of 1H
in lumber DRGs were almost fourfold higher in ob/ob mice
than wild-type mice (P 	 0.001, Fig. 3A). In contrast,
relative expression of mRNA for T-channel isoforms did
not statistically differ when compared in lumbar DRGs
from ob/ob and wild-type mice at age 20–22 weeks (n 
3–5 mice per group, P  0.05, data not shown). In contrast
to our ﬁndings in DRGs, in corresponding lumbar spinal
cord tissue, at age 10–12 weeks, the levels of 1G were not
different; 1H and 1I were slightly decreased in ob/ob
mice (20 and 30%, respectively; n  3–5 mice per group;
P 	 0.05; data not shown). Similar to the ﬁndings in DRGs,
there was no signiﬁcant difference in the levels of mRNA in
either isoform in lumbar spinal cord tissues of the wild-
type and ob/ob groups at the age 20–22 weeks (n  3–5
mice per group, P  0.05, data not shown).
Representative families of T-currents in DRG cells from
wild-type and ob/ob mice are shown in Fig. 3B, which
indicate large enhancement of T-current amplitudes in
ob/ob mice 10–12 weeks old. To establish the magnitude of
the increase and to express it as current density, we
normalized maximal peak T-currents to the cell capaci-
tance. The histograms (Fig. 3C) indicate that T-current
density was enhanced more than twofold in DRG cells
from ob/ob mice as compared with cells from wild-type
mice at the age of 10–12 weeks and 1.5-fold at the age of
16 weeks. However, we did not ﬁnd a signiﬁcant difference
between the two groups at 5–6 weeks, 18 weeks, or 28–30
weeks of age. Thus, it appears that upregulation of T-
currents in DRG neurons coincides with signiﬁcant hyper-
glycemia and the development of severe thermal and
mechanical hypersensitivity. Furthermore, normalization
of T-current density in DRG cells of older ob/ob mice
correlates well with normalization of message for 1H
isoform in DRG tissue homogenates.
Previous in situ hybridization (29) and knockout studies
(30) have established that 1H is a predominant isoform of
T-channels in DRG cells from normal mice. Thus, we
examined the pharmacological properties of these cells in
the ob/ob model of PDN, testing their sensitivity to nickel,
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FIG. 2. Ob/ob mice demonstrated signiﬁcant mechanical (A) and
thermal hypersensitivity (B) that coincided with morbid obesity and
signiﬁcant hyperglycemia (boxed area). A: Ob/ob mice had highly
variable but signiﬁcant mechanical hypersensitivity in both right (F)
and left paws (E)( * P < 0.05) as compared with age-matched wild-type
mice (right paws, f; left paws, ). Peak mechanical hypersensitivity
occurred from 8 to 16 weeks. B: When PWLs were measured, we found
signiﬁcant (*P < 0.001) decreases in both right (F) and left paws (E)
of ob/ob mice as compared with age-matched controls. Although that
peak decrease was detected from 8 to 16 weeks of age, PWL decreases
remained signiﬁcant as compared with those of wild-type mice through-
out the age span. Similarly, there was a signiﬁcant decrease in thermal
PWLs in ob/ob mice from 6 weeks of age as compared with their PWLs
at 4 weeks of age (†P < 0.001) (n  12–18 ob/ob mice; n  12–18 wild
type mice). WT, wild type.
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in DRG cells from control mice (25  7 mol/l, n  4 cells)
versus DRG cells from ob/ob mice (16  3 mol/l, n  8
cells) were very similar (data not shown).
Because development of sensory hypersensitivity and
upregulation of T-current in DRG cells correlates well with
hyperglycemia in ob/ob mice, we administered insulin daily
for 4 weeks (age 8–12 weeks) in ob/ob mice and reasoned
that reversal of hyperglycemia should abolish or at least
diminish hypersensitivity in vivo and upregulation of T-
current density in DRG neurons in vitro. Indeed, daily
insulin treatments resulted in daily blood glucose levels
250 mg/dl (Fig. 4A) and almost complete gradual nor-
malization of both thermal (Fig. 4B) and mechanical (Fig.
4C) hypersensitivity. Importantly, in parallel with the
reversal of hyperalgesia, insulin treatments also com-
pletely reversed upregulation of T-current density. DRG
cells from insulin-treated ob/ob mice (12 weeks old) had an
averaged current density of 87  7% of that from age-
matched wild-type mice (n  13, P  0.05, data not
shown).
Our previous in vitro studies indicated that ECN is a
selective and potent blocker of T-current in DRG cells
(32,33) and has potent peripheral analgesic properties in
vivo (10,22). For these reasons, we performed dose-
response experiments in ob/ob mice at the age when they
are hypersensitive (10–12 weeks of age, Fig. 2) by system-
ically injecting ECN (at 5, 10, or 25 mg/kg i.p.). Responses
to noxious thermal stimuli were recorded over a 5-h period
after the injection (Fig. 5). To conﬁrm the stability of
thermal sensation before injection, we compared the mice
latency times a couple of days before the dose-response
experiment (Fig. B, baseline) with the latency obtained
immediately before injection (0 min). We found no differ-
ence between these recordings for either right (Fig. 5A and
C) or left paws (Fig. 5B and D), although the baseline in
wild-type mice (marked with dotted line) was increased
compared with that in ob/ob mice. On injection of ECN, we
recorded a similar dose-dependent increase in the latency
time in both right (Fig. 5A) and left hind paws (Fig. 5B)o f
ob/ob mice, with the peak effect recorded at 120 min. In
contrast, vehicle injection resulted in steady PWL record-
ings throughout the testing period. The lowest dose of
ECN (5 mg/kg) caused small but signiﬁcant alleviation of
hypersensitivity. At 10 mg/kg, ECN was ineffective in
wild-type mice (Fig. 5C and D, circles) but caused a
signiﬁcant increase in PWLs in ob/ob mice. The highest
dose, 25 mg/kg, although effective in wild-type mice (Fig.
5C and D), had a much more profound effect in ob/ob mice,
with sensitivity at a peak (120 min) similar to the baseline
sensitivity of wild-type mice (dotted line). This suggested
complete, although transient, normalization of thermal
hypersensitivity in ob/ob mice.
To study the effects of ECN on mechanical sensitivity,
we performed a dose-response experiment by determining
the PWRs between 90 and 120 min after its injection. The
choice of this time was based on the timing of the peak
effect on thermal hypersensitivity. Although the lowest
dose (5 mg/kg i.p.) had no effect, 10 mg/kg of ECN caused
signiﬁcant alleviation in mechanical hypersensitivity as
compared with the vehicle in both right (Fig. 6A) and left
(Fig. 6B) paws. Note that the baseline recordings of PWRs
are decreased in wild-type mice (marked with dotted line)
(Fig. 6C, right paw, and D, left paw) and that ECN, at 10
mg/kg, had no effect on mechanical sensitivity in wild-type
mice. The highest dose of ECN, 25 mg/kg, caused a
signiﬁcant decrease (
40%) in the PWRs, resulting in
complete reversal of mechanical hypersensitivity in ob/ob
mice.
To determine speciﬁcity of ECN in vivo in diabetic
animals, we performed a series of experiments with STZ-
injected 1H knockout mice (Fig. 7A), focusing on the
most effective dose of ECN (25 mg/kg i.p.) and using
thermal (Fig. 7B and C) and mechanical (Fig. 7D and E)
sensory testing. STZ-injected 1H/ and age-matched
1H/ mice developed hyperglycemia with blood glu-
cose levels above 400 mg/dl to similar degrees (Fig. 7A,
insert). Interestingly, 1H/ mice did not develop ther-
mal hypersensitivity as evidenced with stable PWLs in
both right and left paws for 4 weeks after injections of
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FIG. 3. Upregulation of T-current in smaller DRG cells after the
development of hyperglycemia in ob/ob mice. A: qRT-PCR analysis of
the relative expression of mRNA for three isoforms of T-channels in
lumbar DRGs and from ob/ob mice and age-matched wild-type controls
at 10–12 weeks of age. There was a fourfold upregulation of 1H
isoform but no signiﬁcant change in 1G and 1I isoforms in lumbar
DRG tissues from ob/ob mice compared with wild-type mice (*P <
0.001). B: Raw current traces evoked in DRG cells from wild-type (top
panel) and ob/ob (bottom panel) mice 10–12 weeks old by voltage
steps from 90 mV (Vh [holding potential]) to Vt (test potential) from
60 through 20 mV in 10-mV increments. Calibrations on top bars
pertain to both panels. Ob/ob mouse had increased absolute amplitude
of isolated T-current more than twofold at a range of test potentials
from 50 to 20 mV. C: Histograms indicate average T-current ampli-
tudes (Vt 30 mV) in DRG cells from wild-type (open bars) and ob/ob
mice (ﬁlled bars) expressed as percent current density normalized to
wild type. The size of each sample is in parentheses; vertical bars are
SE of multiple determinations. Weeks of age for each of the ﬁve
groups are indicated at the bottom. In each group, recordings were
made from at least three mice. At the peak of hyperglycemia and
sensory hypersensitivity (age 10–12 weeks), peak T-current density
averaged 20  4 pA/pF in the wild-type group and 44  7 pA/pF in the
ob/ob group. At 16 weeks of age, T-currents were still signiﬁcantly
upregulated in the ob/ob group by about 1.5-fold, with normalization
occurring at 18 weeks of age. Before the onset (5–6 weeks) and at
the outset of hyperglycemia (28–30 weeks of age), peak T-current
density was not different between the wild-type group and the
ob/ob group (P > 0.05). Asterisk indicates signiﬁcant value by
Mann-Whitney test (P < 0.01); n.s. indicates P > 0.05. HPRT,
hypoxanthine-guanine-phosphoribosyltransferase; WT, wild type.
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hyperalgesia with maximal decrease in PWLs of about 30%
at 1–2 weeks after injections of STZ (Fig. 7A). We next
found that ECN caused a signiﬁcant increase in PWLs in
both paws of diabetic 1H/ littermates (Fig. 7B).
Vehicle injection caused no changes in PWLs throughout
the testing interval (data not shown, n  5 animals). In
contrast, in 1H/ diabetic mice (Fig. 7C), ECN had no
effect on PWLs in either paw. Similarly, when the effect of
ECN on mechanical sensitivity was tested between 90 and
120 min, ECN caused a signiﬁcant decrease in mechanical
hypersensitivity in diabetic 1H/ mice (Fig. 7D) but a
complete lack of effect in diabetic 1H/ mice (Fig. 7E)
in both paws. Similar to absence of the thermal hypersen-
sitivity, diabetic 1H/ mice did not develop mechanical
hypersensitivity because PWRs were not different from
healthy wild-type mice (data not shown). In summary,
these data strongly suggest that 1H channel is required
for the development of early painful PDN in a common
model of STZ-induced diabetes and that diabetic 1H/
mice are insensitive to the analgesic effects of ECN.
We also considered the possibility that ECN might
nonspeciﬁcally decrease thermal and mechanical sensa-
tion by inducing a general depression of behavioral
performance. To determine whether ECN, given at its
maximally effective analgesic dose of 25 mg/kg, causes
sensorimotor disturbances such as motor weakness or
sedation, which could affect the validity of behavioral
sensory testing, we did a battery of sensorimotor tests
focused on agility and ﬁne motor abilities (Fig. 8).
Wild-type (n  5) and ob/ob (n  5) mice at 10–12 weeks
of age were tested using an inclined plane (Fig. 8A),
platform (Fig. 8B), and ledge (Fig. 8C) before ECN
injection and at 90–120 min after injection (at approxi-
mately the peak of the effect of ECN on mechanical and
thermal sensation). The responses of ECN-treated ani-
mals did not signiﬁcantly differ from those responses
before injection on any of these tests, suggesting that
8 9 10 11 12
0
3
4
5
6
8 9 10 11 12
0
200
400
# #
P
W
L
 
(
s
e
c
)
 
(
m
e
a
n
±
S
E
M
)
Age (weeks)
 ob/ob-insulin (right paw)
 ob/ob-insulin (left paw)
 ob/ob-saline (right paw)
 ob/ob-saline (left paw)
 wt-saline (right paw)
 wt-saline (left paw)
#
#
#
*
#
#
†
*
#† *
#† *
#†
Insulin or Saline Treatment
B
C
†
†
# #
#
#
#
G
l
u
c
o
s
e
 
(
m
g
/
d
l
)
 
(
m
e
a
n
±
S
E
M
)
Age (weeks)
 ob/ob-insulin
 ob/ob-saline
 wt-saline
* *
# #
#
†
Insulin or Saline Treatment
A
ob/ob-
insulin
ob/ob-
saline
wt-
saline
0.00
0.03
0.06
F
o
r
c
e
 
(
g
)
 
(
m
e
a
n
+
S
E
M
)
 right paw
 left paw
† *
#
FIG. 4. Insulin treatment alleviates heat and mechanical hypersensitivity in ob/ob mice. Beginning at 8 weeks of age, ob/ob and wild-type mice
were treated with intraperitoneal insulin or saline twice daily. A: Insulin-treated ob/ob mice (f) had reduced blood glucose values by 10 weeks
of age compared with saline-treated ob/ob mice (†P < 0.001) and to original 8-week levels (*P < 0.01). Glucose levels in ob/ob saline-treated mice
(F) were greater than wild-type saline-treated mice () throughout the testing period, while ob/ob insulin-treated mice were only different than
wild-type saline-treated mice during select weeks (#P < 0.05). B: Hypersensitivity in ob/ob insulin-treated mice progressively improved compared
with 8-week values (*P < 0.001) and with ob/ob saline-treated mice (†P < 0.001); however, PWLs remained signiﬁcantly less than wild-type
saline-treated mice (#P < 0.05). C: At 12 weeks of age, mechanical thresholds in ob/ob insulin-treated mice were signiﬁcantly greater than 8-week
values (*P < 0.01) and ob/ob saline-treated mice (*P < 0.05). ob/ob saline-treated mice remained hypersensitive as compared with wild-type
saline-treated mice (#P < 0.05) (n  5 ob/ob mice per group; n  6 wild-type mice). WT, wild type.
T-CHANNELS AND DIABETIC NEUROPATHY
2660 DIABETES, VOL. 58, NOVEMBER 2009 diabetes.diabetesjournals.orgthe effect of ECN on alleviation of neuropathic thermal
and mechanical hypersensitivity is most likely mediated
by T-channels located in the pain pathways.
DISCUSSION
A major ﬁnding of our study is that PDN in hyperglycemic
ob/ob mice is accompanied by pathophysiological distur-
bances in the function of T-channels in sensory neurons.
In particular, we have shown a large increase in the
amplitude of T-currents, with the expression of 1H
mRNA being most affected. T-channel upregulation coin-
cided with behavioral disturbances that usually are indic-
ative of painful PDN, measured as thermal and mechanical
hypersensitivity. Both types of hypersensitivity were dose-
dependently alleviated by ECN, a neuroactive steroid and
selective T-channel antagonist. Based on our behavioral,
biochemical, and biophysical evidence, we propose that
T-channels potentially are important therapeutic targets
for use in the management of painful PDN.
Clinical reports regarding the severity of PDN symptoms
suggest a direct correlation between hyperglycemia and a
propensity for neuropathic pain (NPP)-like pathology,
recommending strict glycemic control as one of the main-
stays of therapy (34). Our ﬁndings with morbidly obese
ob/ob mice conﬁrm that two important signs of NPP,
thermal and mechanical hypersensitivity, coincide with
hyperglycemia; that is, hypersensitivity was most pro-
found in mice between the ages of 8 and 16 weeks and the
improvement of hyperglycemia with insulin alleviated
these hypersensitivities. The lack of mechanical hypersen-
sitivity and decrease in thermal hypersensitivity at ages
later than 20 weeks could be attributed to reduction of
hyperglycemia. However, more permanent changes in
axonal physiology, metabolism, and morphology, includ-
ing decreased nerve conduction velocity, demyelination,
impaired axonal transport, and axonal atrophy, could also
be implicated because they play an important role in
hyposensitivity in later stages of other PDNs (35). Inter-
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eral nerve damage in ob/ob mice using sural nerve
morphometry. However, additional morphometric studies
are needed before conclusively determining whether ob/ob
mice fully recover from hyperglycemia.
In our experiments, thermal and mechanical hypersen-
sitivity in ob/ob mice developed in parallel with hypergly-
cemia and was readily reversed with insulin therapy.
However, another recent study also reported mechanical
hypersensitivity but thermal hyposensitivity of ob/ob mice
(5). No reason for this discrepancy is immediately obvious,
but possibilities include internal biological variability
within the ob/ob mice phenotype; different environmental,
nutritional, and housing conditions; and a difference in the
sensitivity of methods used to measure thermal sensation.
In addition, our study focused on female mice, but it is not
clear what the sex was in the study by Drel et al. Similarly,
variations in the occurrence, duration, modality, and in-
tensity of pain symptoms are well documented among
humans with PDN (3,36–38). Nevertheless, our promising
ﬁndings regarding ECN-induced alleviation of mechanical
and thermal hypersensitivity in hyperglycemic ob/ob mice
suggest that pharmacological antagonism of T-channels in
sensory neurons may offer a great advantage in the treat-
ment of PDN, despite poor control of diabetes.
To the best of our knowledge, this is the ﬁrst report of
a nociceptive ion channel alteration in PDN associated
with morbid obesity. Although an earlier study reported
the upregulation of both T-type and high voltage–activated
(HVA) Ca
2 currents in small DRG cells in a rat model of
type 1 PDN (39), the importance of T-channels was not
further studied. Because our study was not designed to
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we cannot comment on their function in PDN in ob/ob
mice. However, based on our in vivo studies with ECN,
HVA Ca
2 current appears to be an unlikely target for ECN
because this blocker has weak afﬁnity for HVA channels
(32). In addition, the lack of any effect of ECN on mechan-
ical and thermal sensation in diabetic 1H/ mice points
to T-channels as the main target of ECN analgesic action.
Although a causal correlation among the upregulation of
T-currents, enhanced excitability of sensory neurons, and
nociception remains to be conﬁrmed, it is generally ac-
cepted that the hyperexcitability of sensory neurons con-
tributes to allodynia and hyperalgesia, hallmarks of
chronic NPP (40). In that case, T-channel blockade is a
potential therapeutic approach to the treatment of NPP.
However, based on previously published ﬁndings (10) and
the data presented here, it appears that, although signiﬁ-
cant, the alleviation of NPP with ECN is transient. There-
fore, synthesis of ECN-like compounds with a longer effect
or a slow-release formulation of ECN would be beneﬁcial
when repeated administration was indicated.
Possible sites of the analgesic action of ECN other than
the DRG neurons remain to be determined. For example,
being a small lipophilic molecule, ECN could easily cross
the blood-brain barrier to modulate T-channels located in
the dorsal horn neurons, an important pain-processing
region in the central nervous system (41). However, this
appears less likely given that our qRT-PCR data show that
T-channel isoforms in the spinal cord of ob/ob mice are
either not changed (1G) or are already decreased (1I
and 1H), possibly as a compensatory mechanism in
response to diabetes-induced peripheral sensitization to
sensory stimuli. Further studies of ECN pharmacokinetics
will be needed to address this issue.
In conclusion, we have shown that morbidly obese,
hyperglycemic ob/ob mice develop thermal and mechani-
cal hypersensitivity, which usually is indicative of painful
PDN. Their hypersensitivity is accompanied by biochemi-
cal and biophysical modulations of T-channels in DRG
neurons, suggesting that T-channels potentially are a novel
target for treatment of pain in patients with PDN.
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